ANGIODYNAMICS INC — Director's Dealing 2021

Dec 30, 2021

SEC Form 4/A — Form 4/A

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2021-07-14

Reporting Person: Centea Scott (SVP/GM, VIT)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-21	Performance Right	$	A	5684	Acquired		Common Stock (5684)	Direct
2021-07-21	Non-Qualified Stock Option (right to buy)	$26.49	A	7721	Acquired	2031-07-21	Common Stock (7721)	Direct

Footnotes

F1: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of performance rights and stock options of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance rights and the exercise price of the options.

F2: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F3: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.